Condition: Fuchs Endothelial Corneal Dystrophy · Fuchs · Sponsor: Design Therapeutics, Inc.
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
This description comes directly from the study's public registry record.
Mark Daniels · 858-293-4948 · mark@designtx.com
Always discuss trial participation with your own doctor first.
| DTX-168-201 Study Site | Indianapolis, Indiana, United States | Recruiting |
| DTX-168-201 Study Site | Grand Rapids, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07024693